Lower Better for Plaque Regression with PCSK9 Drugs

ACC Conference Reporter

AHA 2016 | NEW ORLEANS — PCSK9 inhibitor treatment atop statins regressed atherosclerotic plaque in an apparently dose-dependent manner, even at extremely low LDL levels, the GLAGOV trial showed. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16


< Back to Listings